clinical_development

Schlieren – September 07, 2026 -- NovaGo Therapeutics AG has closed a Series B financing round of CHF 24 million ($30 million), led by Neurimmune and Pureos, to fund a proof-of-concept trial for its anti-Nogo-A antibody in acute spinal cord injury.

The equity round drew participation from existing and new investors and was supplemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.

NovaGo to enroll 120 patients across Germany, Spain and Switzerland

Proceeds will push the company's lead program, NG004, into a fully randomized, double-blind proof-of-concept study recruiting 120 acute spinal cord injury patients at centers in the three countries. NG004 is a fully human antibody designed to block Nogo-A, a protein that inhibits nerve fiber regeneration and neuroplasticity in the central nervous system.

Sydney – September 04, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has closed an oversubscribed, tranched public offering that generated approximately $40 million in upfront gross proceeds, with total potential proceeds reaching approximately $120 million if milestone-linked warrants are fully exercised.

Offering priced above market with milestone-triggered warrant premiums

The combined offering price was set at $15.50 per American Depositary Share (ADS), with both warrant tranches priced at premiums to that level. Series A Warrants carry an exercise price of $17.825 per ADS, a 15% premium, tied to Kazia's Stage IV triple-negative breast cancer (TNBC) data readout expected in the second half of 2027. Series B Warrants carry an exercise price of $19.375 per ADS, a 25% premium, tied to the company's HR+/HER2- breast cancer data readout expected in the first half of 2028.

CARY, N.C. -- September 01, 2026 -- Veloxis Pharmaceuticals dosed the first participant on Aug. 31, 2026, in its Phase 2 RENGEVITY-201 trial testing pegrizeprument, an investigational immunosuppressive drug, against tacrolimus in kidney transplant recipients. The Cary, North Carolina-based company, a unit of Asahi Kasei Corporation, will enroll up to 120 de novo kidney transplant patients across multiple sites in the randomized, partially blinded study registered as NCT07290777. Patients will receive one of two pegrizeprument doses or tacrolimus, each layered on top of rATG, corticosteroids and mycophenolate maintenance therapy.